[go: up one dir, main page]

IL122102A - Peptides and compounds that bind to a thrombopoietin receptor, pharmaceutical compositions comprising them and their use as medicaments - Google Patents

Peptides and compounds that bind to a thrombopoietin receptor, pharmaceutical compositions comprising them and their use as medicaments

Info

Publication number
IL122102A
IL122102A IL12210296A IL12210296A IL122102A IL 122102 A IL122102 A IL 122102A IL 12210296 A IL12210296 A IL 12210296A IL 12210296 A IL12210296 A IL 12210296A IL 122102 A IL122102 A IL 122102A
Authority
IL
Israel
Prior art keywords
group
peptide
compound
amino acids
peptides
Prior art date
Application number
IL12210296A
Other languages
English (en)
Other versions
IL122102A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL122102A0 publication Critical patent/IL122102A0/xx
Publication of IL122102A publication Critical patent/IL122102A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL12210296A 1995-06-07 1996-06-07 Peptides and compounds that bind to a thrombopoietin receptor, pharmaceutical compositions comprising them and their use as medicaments IL122102A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48530195A 1995-06-07 1995-06-07
US47812895A 1995-06-07 1995-06-07
PCT/US1996/009623 WO1996040750A1 (en) 1995-06-07 1996-06-07 Peptides and compounds that bind to a thrombopoietin receptor

Publications (2)

Publication Number Publication Date
IL122102A0 IL122102A0 (en) 1998-04-05
IL122102A true IL122102A (en) 2002-07-25

Family

ID=27045796

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12210296A IL122102A (en) 1995-06-07 1996-06-07 Peptides and compounds that bind to a thrombopoietin receptor, pharmaceutical compositions comprising them and their use as medicaments

Country Status (26)

Country Link
US (2) US6083913A (es)
EP (4) EP2055712A1 (es)
JP (1) JP3059218B2 (es)
KR (1) KR100436680B1 (es)
CN (2) CN1966520B (es)
AR (1) AR003431A1 (es)
AT (1) ATE390439T1 (es)
BR (1) BR9608587A (es)
CA (2) CA2223449C (es)
CZ (1) CZ291749B6 (es)
DE (1) DE69637473T2 (es)
DK (1) DK0885242T3 (es)
EA (1) EA001220B1 (es)
ES (1) ES2303338T3 (es)
HU (1) HU227678B1 (es)
IL (1) IL122102A (es)
MX (1) MX9709315A (es)
NO (2) NO317737B1 (es)
NZ (1) NZ310778A (es)
PE (1) PE7898A1 (es)
PL (1) PL188795B1 (es)
PT (1) PT885242E (es)
TR (1) TR199701526T1 (es)
TW (1) TW518341B (es)
WO (1) WO1996040750A1 (es)
ZA (1) ZA964814B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
CN1966520B (zh) * 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6172210B1 (en) * 1996-04-02 2001-01-09 Blood Center Research Foundation DNA encoding phospholipid scramblase
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
WO1999052877A1 (en) * 1998-04-14 1999-10-21 Smithkline Beecham Corporation Receptor ligands
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
EP1216037A2 (en) 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) * 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2258558T3 (es) 2000-12-05 2006-09-01 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
JP4145654B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する環状化合物
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2003040885A2 (en) * 2001-11-06 2003-05-15 Drug Design Methodologies, L.L.C. System and method for improved computer drug design
EP1466912B1 (en) * 2002-01-18 2013-04-24 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
CA2485506C (en) 2002-05-17 2012-02-28 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
WO2004016264A1 (ja) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
HRP20050265B1 (hr) * 2002-09-18 2016-05-20 Ortho-Mcneil Pharmaceutical, Inc. Postupci povećanja proizvodnje trombocita i matičnih hematopoetskih stanica
FI20021762A0 (fi) * 2002-10-03 2002-10-03 Karyon Oy Ab Ltd Uusia terapeuttisia aineita ja valmisteita
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
CA2525497A1 (en) 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
AU2004238364A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
AU2004238870B8 (en) 2003-05-12 2010-04-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
BRPI0411160A (pt) 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
WO2004108078A2 (en) * 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
ES2599529T3 (es) 2003-08-12 2017-02-02 Shionogi & Co., Ltd. Compuestos que tienen agonismo hacia el receptor de trombopoyetina
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
AU2004270656B2 (en) * 2003-08-28 2011-03-10 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to thrombopoietin receptors
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
CN100432102C (zh) * 2004-09-30 2008-11-12 百瑞全球有限公司 血小板增进蛋白及其应用
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
TWI351954B (en) 2004-12-08 2011-11-11 Nissan Chemical Ind Ltd Heterocyclic compounds and thrombopoietin receptor
US8134013B2 (en) 2004-12-14 2012-03-13 Nissan Chemical Industries, Ltd. Amide compound and thrombopoietin receptor activator
JP5517450B2 (ja) * 2005-03-10 2014-06-11 バイオンテック アーゲー 二量体または多量体のマイクロタンパク質
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20100145006A1 (en) * 2005-06-23 2010-06-10 Hans-Georg Frank Supravalent compounds
AU2006270801B2 (en) 2005-07-15 2011-12-22 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
KR101290484B1 (ko) 2005-07-20 2013-07-26 닛산 가가쿠 고교 가부시키 가이샤 피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
JP5205967B2 (ja) 2005-11-07 2013-06-05 日産化学工業株式会社 ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
KR20080074166A (ko) * 2005-11-08 2008-08-12 아스테라스 세이야쿠 가부시키가이샤 혈소판감소증을 치료하는 조성물 및 방법
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
ES2470333T3 (es) * 2006-08-08 2014-06-23 Akarx, Inc. Composiciones y métodos para aumentar los niveles de plaquetas de la sangre en humanos
CA2676820A1 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
KR20100027243A (ko) * 2007-07-31 2010-03-10 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 수용체 아고니스트 작용을 갖는 광학 활성인 화합물을 함유하는 의약 조성물 및 그 중간체
US20090088371A1 (en) * 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8278057B2 (en) * 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
US8637455B2 (en) * 2007-10-22 2014-01-28 Affinergy, Llc Compositions and methods for delivery of glycopeptide antibiotics to medical device surfaces
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
CN102428105B (zh) 2009-02-24 2015-09-30 阿雷克森制药公司 含有治疗性tpo/epo模拟肽的抗体
BRPI1014995A2 (pt) * 2009-05-29 2016-04-26 Opko Health Inc ligantes peptídeos para o isolamento e tratamento de células t autoimunes
AU2010254046C1 (en) 2009-05-29 2014-03-06 Novartis Ag Methods of administration of thrombopoietin agonist compounds
KR20120122869A (ko) * 2009-06-02 2012-11-07 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 신경변성 질환을 갖는 대상에서 항체에 의해 인식되는 소분자의 확인법
TW201124726A (en) * 2009-10-16 2011-07-16 Univ Texas Compositions and methods for producing coded peptoid libraries
US8889732B2 (en) 2009-10-23 2014-11-18 Nissan Chemical Industries, Ltd. Fused heterocyclic compounds and thrombopoietin receptor activators
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
CN104045715B (zh) * 2013-03-15 2018-05-01 兰州大学 二聚体化融合蛋白的制备及应用
BR112017003718B1 (pt) * 2014-09-11 2023-04-11 Bristol-Myers Squibb Company Inibidores macrocíclicos das interações de proteína/proteína de pd- 1/pd-l1 e cd80(b7-1)/pd-l1
KR102688415B1 (ko) * 2017-07-26 2024-07-24 잔센파마슈티카엔.브이. 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물
JPWO2021112249A1 (es) * 2019-12-06 2021-06-10
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (es) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
JPH07507806A (ja) 1992-06-11 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド エリスロポエチン薬物送達システム
US5420328A (en) 1992-09-11 1995-05-30 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
CA2150371C (en) * 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1995005843A1 (en) 1993-08-25 1995-03-02 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
AU7843394A (en) 1993-10-27 1995-05-22 Regents Of The University Of California, The Antiviral compounds
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
FI963185A7 (fi) 1994-02-14 1996-08-14 Zymogenetics Inc Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistam iseksi
EP0723456A1 (en) 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
SG79882A1 (en) 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
US5766581A (en) 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
CN1966520B (zh) * 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US8157793B2 (en) 2006-10-25 2012-04-17 Terumo Kabushiki Kaisha Manipulator for medical use
JP7605076B2 (ja) 2021-09-29 2024-12-24 トヨタ紡織株式会社 乗物用シート

Also Published As

Publication number Publication date
EA199700359A1 (ru) 1998-10-29
KR100436680B1 (ko) 2004-09-18
PL323917A1 (en) 1998-04-27
TW518341B (en) 2003-01-21
CN1966520A (zh) 2007-05-23
HK1015380A1 (en) 1999-10-15
CN1966520B (zh) 2012-07-11
DE69637473D1 (de) 2008-05-08
CA2636432A1 (en) 1996-12-19
PE7898A1 (es) 1998-03-05
AU6163496A (en) 1996-12-30
CA2223449A1 (en) 1996-12-19
EP1961760A3 (en) 2008-09-03
HUP9900921A2 (hu) 1999-07-28
MX9709315A (es) 1998-08-30
HU227678B1 (en) 2011-11-28
EP2338897A1 (en) 2011-06-29
AU704215B2 (en) 1999-04-15
BR9608587A (pt) 1999-01-05
CA2223449C (en) 2008-10-07
EA001220B1 (ru) 2000-12-25
US6465430B1 (en) 2002-10-15
PL188795B1 (pl) 2005-04-29
CN1315870C (zh) 2007-05-16
CA2636432C (en) 2012-01-03
US6083913A (en) 2000-07-04
EP0885242A4 (en) 2000-03-22
NO975705L (no) 1998-02-05
NO975705D0 (no) 1997-12-05
CN1192749A (zh) 1998-09-09
CZ291749B6 (cs) 2003-05-14
JPH10507776A (ja) 1998-07-28
AR003431A1 (es) 1998-08-05
WO1996040750A1 (en) 1996-12-19
DK0885242T3 (da) 2008-07-14
EP2055712A1 (en) 2009-05-06
ATE390439T1 (de) 2008-04-15
PT885242E (pt) 2008-06-18
EP0885242B1 (en) 2008-03-26
NO331550B1 (no) 2012-01-23
JP3059218B2 (ja) 2000-07-04
ES2303338T3 (es) 2008-08-01
KR19990022576A (ko) 1999-03-25
NO317737B1 (no) 2004-12-13
NO20041296L (no) 1998-02-05
EP0885242A1 (en) 1998-12-23
CZ389797A3 (cs) 1998-06-17
HUP9900921A3 (en) 1999-11-29
NZ310778A (en) 1999-10-28
EP1961760A2 (en) 2008-08-27
TR199701526T1 (xx) 1998-03-21
DE69637473T2 (de) 2009-05-07
ZA964814B (en) 1998-02-09
IL122102A0 (en) 1998-04-05

Similar Documents

Publication Publication Date Title
IL122102A (en) Peptides and compounds that bind to a thrombopoietin receptor, pharmaceutical compositions comprising them and their use as medicaments
US5932546A (en) Peptides and compounds that bind to the thrombopoietin receptor
US6251864B1 (en) Peptides and compounds that bind to a receptor
US6121238A (en) Peptides and compounds that bind to a receptor
US20090214489A1 (en) Peptides and compounds that bind to a receptor
WO1996040189A1 (en) Peptides and compounds that bind to a receptor
CZ134099A3 (cs) Inhibitory serinových proteáz, zejména proteázy viru hepatitidy C NS3
AU2004270656B2 (en) Peptides and compounds that bind to thrombopoietin receptors
US20060040866A1 (en) Peptides and compounds that bind to a receptor
AU704215C (en) Peptides and compounds that bind to a thrombopoietin receptor
HK1015380B (en) Peptides and compounds that bind to a thrombopoietin receptor
HK1124620A (en) Peptides and compounds that bind to a thrombopoietin receptor
HK1163698A (en) Peptides and compounds that bind to a receptor
HK1163698B (en) Peptides and compounds that bind to a receptor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired